A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C
Latest Information Update: 12 May 2022
At a glance
- Drugs Anacetrapib (Primary)
- Indications Hypercholesterolaemia; Low HDL cholesterol
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors Merck Sharp & Dohme
- 25 Jun 2019 This trial has been completed in United Kingdom, according to European Clinical Trials Database.
- 21 Jun 2019 Trial has been completed in Romania, according to European Clinical Trials Database record.
- 01 Nov 2016 Primary endpoint (Percent Change from Baseline in HDL-C) has been met, according to the results published in the American Journal of Cardiology